Target Price | $314.96 |
Price | $316.04 |
Deviation | 0.34% |
Number of Estimates | 23 |
23 Analysts have issued a price target Amgen 2026 . The average Amgen target price is $314.96. This is 0.34% lower than the current stock price. The highest price target is $389.00 23.09% , the lowest is $185.00 41.46% . | |
A rating was issued by 32 analysts: 15 Analysts recommend Amgen to buy, 14 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Amgen stock has an average upside potential 2026 of 0.34% . Most analysts recommend the Amgen stock at Purchase. |
25 Analysts have issued a sales forecast Amgen 2025 . The average Amgen sales estimate is $35.2b . This is 5.91% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $35.9b 8.08% , the lowest is $34.6b 4.18% .
This results in the following potential growth metrics:
2024 | $33.2b | 18.64% |
---|---|---|
2025 | $35.2b | 5.91% |
2026 | $36.0b | 2.29% |
2027 | $36.6b | 1.55% |
2028 | $36.8b | 0.53% |
2029 | $38.0b | 3.51% |
10 Analysts have issued an Amgen EBITDA forecast 2025. The average Amgen EBITDA estimate is $18.0b . This is 25.44% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $21.4b 49.41% , the lowest is $14.3b 0.12% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $13.9b | 12.54% |
---|---|---|
2025 | $18.0b | 29.17% |
2026 | $18.1b | 0.83% |
2027 | $18.7b | 3.31% |
2028 | $18.4b | 1.89% |
2029 | $18.3b | 0.50% |
2024 | 41.84% | 5.15% |
---|---|---|
2025 | 51.03% | 21.96% |
2026 | 50.30% | 1.43% |
2027 | 51.18% | 1.75% |
2028 | 49.95% | 2.40% |
2029 | 48.01% | 3.88% |
9 Amgen Analysts have issued a net profit forecast 2025. The average Amgen net profit estimate is $5.9b . This is 46.04% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $7.8b 91.92% , the lowest is $4.0b 0.24% .
This results in the following potential growth metrics and future Net Margins:
2024 | $4.1b | 39.47% |
---|---|---|
2025 | $5.9b | 45.84% |
2026 | $6.5b | 10.39% |
2027 | $8.9b | 36.53% |
2028 | $9.2b | 3.03% |
2029 | $11.1b | 20.54% |
2024 | 12.21% | 48.98% |
---|---|---|
2025 | 16.82% | 37.71% |
2026 | 18.15% | 7.91% |
2027 | 24.40% | 34.44% |
2028 | 25.01% | 2.50% |
2029 | 29.12% | 16.43% |
9 Analysts have issued a Amgen forecast for earnings per share. The average Amgen EPS is $11.03 . This is 46.09% higher than earnings per share in the financial year 2024. The highest EPS forecast is $14.49 91.92% , the lowest is $7.53 0.26% .
This results in the following potential growth metrics and future valuations:
2024 | $7.56 | 39.47% |
---|---|---|
2025 | $11.03 | 45.90% |
2026 | $12.17 | 10.34% |
2027 | $16.62 | 36.57% |
2028 | $17.12 | 3.01% |
2029 | $20.64 | 20.56% |
Current | 41.88 | 94.43% |
---|---|---|
2025 | 28.66 | 31.57% |
2026 | 25.97 | 9.39% |
2027 | 19.02 | 26.76% |
2028 | 18.46 | 2.94% |
2029 | 15.31 | 17.06% |
Based on analysts' sales estimates for 2025, the Amgen stock is valued at an EV/Sales of 6.21 and an P/S ratio of 4.82 .
This results in the following potential growth metrics and future valuations:
Current | 6.58 | 7.19% |
---|---|---|
2025 | 6.21 | 5.57% |
2026 | 6.07 | 2.24% |
2027 | 5.98 | 1.53% |
2028 | 5.95 | 0.52% |
2029 | 5.75 | 3.39% |
Current | 5.11 | 0.69% |
---|---|---|
2025 | 4.82 | 5.58% |
2026 | 4.72 | 2.24% |
2027 | 4.64 | 1.52% |
2028 | 4.62 | 0.53% |
2029 | 4.46 | 3.39% |
Analyst | Rating | Action | Date |
---|---|---|---|
B of A Securities |
Underperform
➜
Underperform
|
Unchanged | Mar 05 2025 |
Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Feb 10 2025 |
B of A Securities |
Underperform
➜
Underperform
|
Unchanged | Feb 06 2025 |
Citigroup |
Neutral
➜
Neutral
|
Unchanged | Jan 28 2025 |
RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Jan 24 2025 |
Wells Fargo |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Jan 10 2025 |
Truist Securities |
Hold
➜
Hold
|
Unchanged | Jan 08 2025 |
Analyst Rating | Date |
---|---|
Unchanged
B of A Securities:
Underperform
➜
Underperform
|
Mar 05 2025 |
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Feb 10 2025 |
Unchanged
B of A Securities:
Underperform
➜
Underperform
|
Feb 06 2025 |
Unchanged
Citigroup:
Neutral
➜
Neutral
|
Jan 28 2025 |
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Jan 24 2025 |
Unchanged
Wells Fargo:
Equal-Weight
➜
Equal-Weight
|
Jan 10 2025 |
Unchanged
Truist Securities:
Hold
➜
Hold
|
Jan 08 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.